Development starkt i Q3 medan Production var svagt Arise rapporterade ett starkt Q3'22 med EBIT om 6...
Redey is happy to see Image Systems delivering very strong Q3 numbers, with earnings and margins at ...
Sales SEK 18.8m, -35% vs. ABGSCe SEK 28.9m EBITDA SEK -1.
IFreja’s Q3 report confirmed our positive views and our concerns.
Redeye is pleased that Bioservo’s Carbonhand 2.0 has now been classified and approved as a medical d...
Media and Games Invest’s (MGI’s) recent EGM confirmed that the group can now proceed with its reloca...
Q3 adj. EBITA -20% vs ABGSCe due to North America Guides for recovery in Q4 and reiterates 2022 guid...
Adj. EBIT SEK 130m (+65% vs. ABGSCe 79m) Still looking to divest Russian business 1.
Redeye comments on Alzecure’s Q3 report, which came in as expected.
Redeye states that the Q3 report was more or less in line with estimates, albeit somewhat on the low...
Redeye updates estimates and valuation in G5 following its Q3-results.
Redeye leaves its fair value range unchanged on the back of this Q3 report, which was in line with o...
Redeye is encouraged by TH1NG announcing it has won the public procurement from Jönköping Municipali...
Redeye embraces the strong gross margin of 84% vs REe of 80% in the quarter, and we judge the slight...
Redeye comments on Cantargia's third quarter report and events after the end of the quarter, includi...
Redeye comments on Ultimovacs’ Q3 2022 report, as the company’s lead candidate is approaching its pr...
With activity picking up from mid-September onwards, as expected, we are optimistic about Raketech's...
Redeye retains its positive view on Vertiseit following a solid Q3, with margins beating our forecas...
The 3rd of November, Eevia Health (“Eevia” or “the company”) announced that the company has develope...
Redeye states that Q3 revenues are still not satisfactory but that it’s good that the burn rate is k...
